Sarcopenia Predicts Immune-related Adverse Events Due to Anti-PD-1/PD-L1 Therapy in Patients with Advanced Lung Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Oct 8

PMID 39376979

Authors

Dinglong Xue

Ning Li

Jiaxin Yang

Kaiya Men

Lijun Li

Hao Jiang

Xu Zhao

Shuai Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of a number of patients with advanced cancer, and while this has resulted in increased survival times, it has also led to the emergence of novel immune-related adverse events (irAEs). In individuals with advanced cancer, sarcopenia is a significant symptom of cachexia and is linked to poor nutritional status and increased mortality. The present study aimed to evaluate sarcopenia and other risk variables that can affect the emergence of irAEs in patients with lung cancer.

Methods: A single-center retrospective analysis of 129 patients with advanced lung cancer treated with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) checkpoint inhibitors was conducted from August 2020 to August 2022. Data on baseline characteristics and adverse events of participants were collected. Computed tomography was used to determine the skeletal muscle index at the third lumbar vertebra (L3-SMI) and whether sarcopenia is present.

Results: The median age of all participants was 60 years old (range, 52-66 years), with men accounting for 68.9% of the total patient cohort. The present study showed that 44 (34%) participants presented with any degree of irAEs, and 79 (61.2%) patients presented with sarcopenia. There were no statistically significant differences in baseline characteristics, such as age and sex, between patients who presented with irAEs and those without irAEs. Using logistic regression analysis, individuals with sarcopenia were 2.635-times more likely to experience any grade of irAEs than those without sarcopenia.

Discussion: irAEs are prevalent side effects of PD-1/PD-L1 inhibitor therapy for patients with cancer. By diagnosing and treating sarcopenia early, it is possible to lower the potential risk of irAEs in patients with advanced cancer. Furthermore, sarcopenia can be utilized as a predictor of irAEs.

References

Rogado J, Sanchez-Torres J, Romero-Laorden N, Ballesteros A, Pacheco-Barcia V, Ramos-Levi A . Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019; 109:21-27. DOI: 10.1016/j.ejca.2018.10.014. View

Mourtzakis M, Prado C, Lieffers J, Reiman T, McCargar L, Baracos V . A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997-1006. DOI: 10.1139/H08-075. View

Wang J, Yang L, Wang H, Cui S, Gao Y, Hu B . Anti-PD-1 therapy reverses TIGITCD226NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR/TIGIT pathway. Int Immunopharmacol. 2024; 130:111681. DOI: 10.1016/j.intimp.2024.111681. View

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C . Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14):1328-1339. DOI: 10.1056/NEJMoa1917346. View

Zhi W, Dreyfus N, Lessing A, Galantino M, Piulson L, Liu Kot K . Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis. Oncologist. 2023; 28(7):604-608. PMC: 10322124. DOI: 10.1093/oncolo/oyad062. View

Wang D, Salem J, Cohen J, Chandra S, Menzer C, Ye F . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(12):1721-1728. PMC: 6440712. DOI: 10.1001/jamaoncol.2018.3923. View

Rathbun A, Shardell M, Ryan A, Yau M, Gallo J, Schuler M . Association between disease progression and depression onset in persons with radiographic knee osteoarthritis. Rheumatology (Oxford). 2020; 59(11):3390-3399. PMC: 7590406. DOI: 10.1093/rheumatology/keaa141. View

Cortellini A, Bozzetti F, Palumbo P, Brocco D, Marino P, Tinari N . Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Sci Rep. 2020; 10(1):1456. PMC: 6989679. DOI: 10.1038/s41598-020-58498-2. View

10.

Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos F, Romano-Martin P . The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Eur J Cancer. 2021; 158:217-224. DOI: 10.1016/j.ejca.2021.08.048. View

11.

Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K . Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of.... Eur J Cancer. 2020; 128:17-26. DOI: 10.1016/j.ejca.2019.12.031. View

12.

Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

13.

Guzman-Prado Y, Ben Shimol J, Samson O . Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review. Cancer Immunol Immunother. 2021; 70(10):2771-2780. PMC: 10991997. DOI: 10.1007/s00262-021-02888-6. View

14.

Daly L, Power D, OReilly A, Donnellan P, Cushen S, OSullivan K . The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017; 116(3):310-317. PMC: 5294486. DOI: 10.1038/bjc.2016.431. View

15.

Mir O, Coriat R, Blanchet B, Durand J, Boudou-Rouquette P, Michels J . Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012; 7(5):e37563. PMC: 3364283. DOI: 10.1371/journal.pone.0037563. View

16.

Kong M, Geng N, Zhou Y, Lin N, Song W, Xu M . Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study. Clin Nutr. 2022; 41(2):396-404. DOI: 10.1016/j.clnu.2021.12.003. View

17.

Postow M, Callahan M, Wolchok J . Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. PMC: 4980573. DOI: 10.1200/JCO.2014.59.4358. View

18.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P . Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs. 2017; 35(4):436-441. DOI: 10.1007/s10637-017-0464-x. View

19.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

20.

Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K . Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci Rep. 2019; 9(1):2447. PMC: 6385253. DOI: 10.1038/s41598-019-39120-6. View